First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.

Claudia Vener, Rita Banzi, Federico Ambrogi, Annalisa Ferrero, Giuseppe Saglio, Gabriella Pravettoni, Milena Sant

Research output: Contribution to journalArticlepeer-review

Abstract

Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), improves overall survival (OS), but the introduction of newer TKIs requires the definition of the optimal first-line TKI for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase (CP) CML. This systematic review of randomized controlled trials (RCTs) compares the efficacy and safety of imatinib vs second-generation (dasatinib, nilotinib, bosutinib) and third-generation TKIs (ponatinib) in adults with newly diagnosed Ph+ CP CML, concentrating on OS, progression-free survival (PFS), and hematological and nonhematological adverse events. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. Seven RCTs published between 1990 and 2019 (involving 3262 participants) satisfied the eligibility criteria. Two RCTs (imatinib vs nilotinib and imatinib vs dasatinib) found no difference in 5-year OS or PFS. Second- and third-generation TKIs improved 3-month major molecular responses (relative risk [RR], 4.28; 95CI], 2.20-8.32) and other efficacy outcomes, decreased accelerated/blastic-phase transformations (RR, 0.44; 95 0.26-0.74), but were associated with more cases of thrombocytopenia (RR, 1.57; 95 1.20-2.05), cardiovascular events (RR, 2.54; 95 1.49-4.33), and pancreatic (RR, 2.29; 95 1.32-3.96) and hepatic effects (RR, 3.51; 95.55-7.92). GRADE showed that the certainty of the evidence ranged from high to moderate. This study shows that, in comparison with imatinib, second- and third-generation TKIs improve clinical responses, but the safer toxicity profile of imatinib may make it a better option for patients with comorbidities.
Original languageEnglish
JournalBlood advances
Issue number12
Publication statusPublished - Jun 1 2020

Fingerprint Dive into the research topics of 'First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.'. Together they form a unique fingerprint.

Cite this